Skip to main content

Table 4 Adverse events in all patients with chronic HCV infection

From: Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Variables Total PEG-IFN alfa-2a PEG-IFN alfa-2b P*
  (N=661) (N=402) (N=259)  
Overall AE, N (%) 542 (82.0) 312 (77.6) 230 (88.8)  
 Grade 1-2/3 493/49 (91.0/9.0) 288/24 (92.3/7.7) 205/25 (89.1/10.9) 0.23
Common AE, N (%)     
  Flu-like symptoms     
  Grade 1-2/3 421/0 (63.7/0) 229/0 (57.0/0) 192/0 (74.1/0) <0.01
  GI symptoms     
  Grade 1-2/3 152/11 (23.0/1.7) 82/6 (20.4/1.5) 70/5 (27.0/1.9) 0.12
 Dermatologic reactions     
  Grade 1-2/3 74/2 (11.2/0.3) 38/1 (9.5/0.2) 36/1 (13.9/0.4) 0.19
  Emotional friability     
  Grade 1-2/3 183/23 (27.7/3.5) 102/11 (25.4/2.7) 81/12 (31.3/4.6) 0.08
 Alopecia     
  Grade 1-2/3 96/20 (14.5/3.0) 50/7 (12.4/1.7) 46/13 (17.8/5.0) <0.01
Hematologic events, N (%)     
 ANC, <500/mm3 3 (0.5) 0 (0) 3 (1.2) 0.06
 Hemoglobin, <8.5 g/dL 25 (3.8) 15 (3.7) 10 (3.9) 1.00
 Platelet, <25,000/mm3 6 (0.9) 6 (1.5) 0 (0) 0.09
Serious AE, N (%)     
 Severe infection or death 2 (0.3) 2 (0.5) 0 (0) 0.52
Patients who did not meet 80/80/80 rule 181 (27.4) 118 (29.4) 63 (24.3) 0.18
 Dose modification, N (%) 82 (45.3) 58 (49.23) 24 (38.1) 0.16
 Discontinuation, N (%) 99 (54.7) 60 (60.6) 39 (39.4) 0.52
  AE/hematologic event 47 (47.5) 27 (45.0) 20 (51.3) 0.68
  Non-virologic response 18 (18.2) 10 (16.7) 8 (20.5) 0.79
  Incidental severe infection 2 (2.0) 2 (3.3) 0 (0) 0.52
  Follow-up loss 32 (32.3) 21 (35.0) 11 (28.2) 0.48
  1. Abbreviation: HCV, hepatitis C virus; AE, adverse event; GI, gastrointestinal; ANC, absolute neutrophil count; PEG-IFN, peg-interferon; NA, not available.
  2. *P-value stands for comparison of the frequency of adverse event or each variable between the PEG-IFN alfa-2a and PEG-IFN alfa-2b groups.
  3. Most severe grade among adverse events that patients had experienced during treatment.
  4. If the number of patients was smaller than 5, Fisher’s exact test was used.